Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclooctane SCHEMBL28098731 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| Cyclohexane SCHEMBL7376420 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| Cycloheptane SCHEMBL27831919 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| Ether SCHEMBL232500 | 1.00 | — | — | |
| Cyclopentane SCHEMBL8923462 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| Cyclohexane SCHEMBL2297628 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| Cyclohexane SCHEMBL8441380 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| Cyclohexane SCHEMBL251247 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| Cyclohexane SCHEMBL8441382 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHR | |
| Cyclohexane SCHEMBL9286703 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361920-A2 | Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity | Kemin Pharma Europe (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-2168972-A2 | Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity | Kemin Pharma Europe (US) | 2010-03-31 | — | — | EP | disclosed |
| US-7534871-B2 | Carbohydrate scaffold, carrying two side chains, which form a macrocyclic ring that may be unsaturated and contains ether, amide, ester and/or carbamate groups; for therapy of bacterial, fungal, viral or protozoal infections or tumors | KEMIN PHARMA B.V.B.A. (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1446391-A4 | PREPARATION AND USE OF CARBOHYDRATE-BASED RING STRUCTURES WITH ANTIMICROBIAL AND CYTOSTATIC ACTIVITY | KEMIN PHARMA EUROP (US) | 2008-02-20 | — | — | EP | disclosed |
| US-7138531-B2 | Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity | KEMIN PHARMA B.V.B.A. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7101908-B2 | Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae | KEMIN PHARMA EUROPE B.V.B.A. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1590357-A2 | BICYCLIC CARBOHYDRATE COMPOUNDS USEFUL IN THE TREATMENT OF INFECTIONS CAUSED BY FLAVIVIRIDAE SP., SUCH AS HEPATITIS C AND BOVINE VIRAL DIARRHEA VIRUSES | Kemin Pharma Europe BVBA (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005062748-A2 | BICYCLIC CARBOHYDRATE COMPOUNDS USEFUL IN THE TREATMENT OF INFECTIONS CAUSED BY HERPESVIRIDAE | KEMIN PHARMA EUROPE B.V.B.A. (BE) | 2005-07-14 | — | — | WO | disclosed |
| US-20040224904-A1 | Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity | SAS BENEDIKT (BE) | 2004-11-11 | — | — | US | disclosed |
| EP-1446391-A2 | PREPARATION AND USE OF CARBOHYDRATE-BASED RING STRUCTURES WITH ANTIMICROBIAL AND CYTOSTATIC ACTIVITY | Kemin Pharma Europe (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2004062575-A2 | BICYCLIC CARBOHYDRATE COMPOUNDS USEFUL IN THE TREATMENT OF INFECTIONS CAUSED BY FLAVIVIRIDAE SP., SUCH AS HEPATITIS C AND BOVINE VIRAL DIARRHEA VIRUSES | KEMIN PHARMA EUROPE BVBA (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004062590-A2 | BICYCLIC CARBOHYDRATES AS ANTIPROTOZOAL BIOACTIVE FOR THE TREATMENT OF INFECTIONS CAUSED BY PARASITES | KEMIN PHARMA EUROPE B.V.B.A. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20030158243-A1 | Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity | KEMIN PHARMA EUROPE (BE) | 2003-08-21 | — | — | US | disclosed |
| WO-2003032905-A2 | PREPARATION AND USE OF CARBOHYDRATE-BASED RING STRUCTURES WITH ANTIMICROBIAL AND CYTOSTATIC ACTIVITY | KEMIN PHARMA EUROPE (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158243-A1 | Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity | MANBA, MAN2B1, MAN1B1 | ALDH1A1 2417/4885TSHR 4382/4885 |
| US-20040224904-A1 | Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity | MANBA, MAN2B1, MAN1B1 | ALDH1A1 2417/4885TSHR 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.